جست‌وجوی استاد و پژوهشگر

Syed Hani Hassan Abidiمشاهده پروفایل

دانشیار

• Virology
• Immunology
• Viral Oncology
• +۷ مورد دیگر

Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .

Allison Ross Eckardمشاهده پروفایل

استاد

• HIV-related cardiometabolic complications
• Antiretroviral therapy optimization
• Pediatric infectious diseases
• +۷ مورد دیگر

Allison Ross Eckard, MD is Professor in the Departments of Pediatrics and Medicine at the Medical University of South Carolina (MUSC) College of Medicine, serving as Division Chief for Pediatric Infectious Diseases and Director of MUSC's Ryan White Pediatric HIV Clinic and HIV Transition Clinic. She maintains an adjunct faculty position at Emory University and holds board certification in Pediatrics and Pediatric Infectious Diseases. Her primary research focuses on metabolic, cardiovascular, and nutritional complications of chronic HIV and antiretroviral therapy across age groups, with emphasis on inflammation's role in comorbidities like cardiovascular disease and bone disorders. Current investigations include NIH R01-funded research on interventions for weight gain and abdominal fat in HIV, vitamin D supplementation, and statin therapy. She has published nearly 60 peer-reviewed papers on HIV pathogenesis and treatment optimization. Dr. Eckard co-chairs the DHHS panel for Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children and serves on the DHHS panel for Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV . Her clinical work specializes in comprehensive HIV care for children through young adults, with particular focus on adolescent/young adult transition issues and global health initiatives through Lespwa Timoun in Haiti. Recent efforts include developing COVID-19 treatment guidelines for children and school safety protocols. HIV Specialist certification (American Academy of HIV Medicine) Fellow, Infectious Diseases Society of America Fellow, Pediatric Infectious Diseases Society Fellow, HIV Medical Association Member, HIV Medical Association's 'Ending the HIV Epidemic' working group She leads MUSC's HIV education initiatives and serves as inpatient consultant for pediatric infectious diseases, with advanced training in tropical medicine. Her NIH-funded research examines targeted interventions to minimize comorbidity development in HIV, while her clinical leadership spans the Ryan White HIV program, transition clinics, and global health partnerships.

Paul Stuppleمشاهده پروفایل

استاد

• Small Molecule Drug Discovery
• Cancer Therapeutics
• Pharmaceutical Chemistry
• +۳ مورد دیگر

Prof. Paul Stupple is a Professor of Medicinal Chemistry at Monash University, Australia, with over 20 years' experience in pharmaceutical industry and academia. He holds leadership roles at Canthera Discovery and manages the Australian Translational Medicinal Chemistry Facility. His expertise lies in small molecule drug discovery, particularly targeting cancer therapies and epigenetic regulators. Affiliations: Monash University, Faculty of Pharmacy and Pharmaceutical Sciences Canthera Discovery (Director, Medicinal Chemistry) Education: BA and DPhil in Chemistry from the University of Oxford (1992–1999). Early career at Pfizer as a medicinal chemistry leader, delivering 6 clinical candidates. Key contributions include: Licensing deals with Merck (2016) and Pfizer (2018) for preclinical projects Leading the Cancer Therapeutics CRC's medicinal chemistry program Research Interests: Small molecule drug discovery focused on histone acetyltransferase inhibitors, cancer therapeutics, and epigenetic modulation. Notable projects include development of KAT6A/B inhibitors for ER+ breast cancer and STING agonists for immunotherapy. Grants/Projects: Principal Investigator for major initiatives like MedChem Australia (2023–2028) and drug target identification platforms. Collaborates widely with institutions like WEHI and University of Sydney. Over 28 peer-reviewed publications spanning 1997–2025. Labs/Teams: Oversees the Australian Translational Medicinal Chemistry Facility, a key resource for drug discovery in Australia.

Vadim Cherezovمشاهده پروفایل

استاد

• Membrane Protein Structure and Function
• G Protein-Coupled Receptors (GPCRs)
• Lipid-Protein Interactions
• +۳ مورد دیگر

Vadim Cherezov, the Ester Dornsife Chair in Biological Sciences and Professor at the University of Southern California (USC), leads groundbreaking research in membrane protein structure and function. Affiliated with the Bridge Institute, Department of Chemistry, and Michelson Center for Convergent Bioscience, his work focuses on GPCRs, ion channels, and transporters—critical targets for drug discovery. His team leverages advanced techniques like Lipidic Cubic Phase (LCP) and Serial Femtosecond Crystallography (SFX) at XFEL facilities to solve high-resolution structures under physiological conditions. Institutional Affiliations: Bridge Institute, USC Michelson Center, Department of Chemistry, Department of Pharmacology and Pharmaceutical Sciences. Key Collaborations: Katritch Lab, Kuhn Lab, NIH, European XFEL. His research explores the role of lipids in modulating GPCR function, addressing diseases like Alzheimer’s, diabetes, and cancer. By solving the structure of the A 2A adenosine receptor via sulfur SAD phasing at XFEL, Cherezov’s lab demonstrated de novo phasing without heavy atoms. This breakthrough enables structural studies of previously intractable membrane proteins. Scientific Awards & Grants: NIH R01 GM108635, U54 GM094618, U54 GM094599, R01 GM095583 Science Signaling Breakthroughs of the Year (2014) Cherezov mentors a dynamic team, including postdocs (e.g., Dong-Gyun Kim), graduate students (e.g., Behnaz Davoudinasab), and alumni (e.g., Benjamin Stauch at Eli Lilly, Nairie Michaelian at Genentech). His lab’s publications span Nature , Science , and Cell , with recent work on Science Advances (2025) addressing ABEL-FRET for GPCR dynamics.

• Pharmacology
• Traditional Chinese Medicine
• Cancer Therapy
• +۷ مورد دیگر

Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.

Kelly Arnoldمشاهده پروفایل

دانشیار

• Biomedical Computation and Modeling
• Drug Delivery and Therapeutics
• Systems Immunology
• +۵ مورد دیگر

Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.

• Longitudinal Data Analysis
• Time-to-Event Analysis
• Survival Analysis
• +۵ مورد دیگر

Alessandra Meddis serves as an Assistant Professor in the Section of Biostatistics within the Department of Public Health at the University of Copenhagen's Faculty of Health and Medical Sciences. Her academic work centers on developing and applying advanced statistical methodologies for longitudinal and time-to-event data analysis, with significant contributions to public health research in Denmark and internationally. Her institutional affiliation is clearly established through university contact details and departmental listings. Her primary research interests include correlated survival data analysis, competing risk modeling, informative cluster size methodology, causal inference techniques for observational studies, and environmental epidemiology applications. Dr. Meddis has developed specialized expertise in handling complex survival data structures while maintaining focus on real-world public health problems, particularly in HIV comorbidity patterns, environmental exposure effects, and pandemic-related mortality analyses. Her methodological innovations directly address challenges in clustered and censored data common across medical research domains. Analysis of Dr. Meddis's recent publication record reveals a consistent trajectory of high-impact interdisciplinary research spanning clinical medicine, epidemiology, and statistical methodology. Her work appears in leading journals across biostatistics, infectious diseases, and public health, demonstrating strong collaborative networks with clinical researchers and epidemiologists. Key thematic areas include HIV treatment outcomes, environmental health exposures, and critical care applications during the pandemic, with recent methodological papers advancing survival analysis techniques for complex data structures. Scientific Awards: No scientific awards were specified in the available institutional profile. Advising and Grants: The institutional profile does not provide details regarding graduate student supervision or specific research grant funding. Her collaborative publications suggest involvement in multi-investigator projects including the COCOMO HIV cohort study and pandemic-related research initiatives. Labs and Teams: Dr. Meddis is affiliated with the Section of Biostatistics within the Department of Public Health, though specific laboratory facilities or dedicated research teams are not described in the source material. Her extensive co-authorship patterns indicate active participation in multiple research consortia across medical specialties.

Zach Shahnمشاهده پروفایل

استادیار

• Causal Inference
• Healthcare Data Analysis
• Critical Care Applications
• +۳ مورد دیگر

Zach Shahn is an Assistant Professor in the Department of Epidemiology and Biostatistics at the CUNY School of Public Health. He holds a PhD in Statistics from Columbia University and a BA in Mathematics from Stanford University. His research focuses on causal inference methods applied to healthcare data, particularly time-varying treatment effects and critical care applications. He has conducted postdoctoral work at Harvard School of Public Health and previously worked at IBM Research in Healthcare and Life Sciences. Education: PhD in Statistics and Probability, Columbia University BA in Mathematics, Stanford University Research interests include developing causal inference frameworks for evaluating treatment efficacy in dynamic healthcare settings, with a focus on critical care outcomes and methodological innovations. Recent work explores applications of causal diagrams, instrumental variables, and machine learning in healthcare decision-making. His studies often involve large-scale healthcare datasets to assess interventions' real-world impacts. Key trends in his articles include advancements in causal effect estimation under complex treatment regimes, bias analysis in observational studies, and methodological contributions to difference-in-differences and N-of-1 trial designs. His work bridges statistical theory with practical healthcare challenges, emphasizing reproducibility and policy relevance. No scientific awards are listed, though his contributions to causal inference methodologies are notable in academic circles. He has advised on healthcare data projects and published extensively without explicitly listed grants. His professional network includes collaborations with institutions like Harvard and IBM. He is affiliated with CUNY's public health programs and actively engages in academic discourse via Twitter and LinkedIn. His lab or team details are not explicitly mentioned in available materials.

Owen O'Donnellمشاهده پروفایل

استاد

• Health Economics
• Health Inequality
• Health Insurance & Financial Protection
• +۴ مورد دیگر

Owen O'Donnell is a Full Professor of Applied Economics at the Erasmus School of Economics and Erasmus School of Health Policy & Management , Erasmus University Rotterdam. He is a Research Fellow at the Tinbergen Institute and an Editor of the Journal of Health Economics . Education: DPhil, University of York (UK) Research Interests: His work focuses on health economics, including health inequality, health insurance, financial protection, and labor economics, with applications in low-, middle-, and high-income countries. He employs cross-sectional analyses, equity-sensitive frameworks, and global health policy evaluation. Publications & Collaborations: He has published extensively in top journals like Lancet , PLOS Medicine , and Demography , addressing cardiovascular disease, hypertension screening, and healthcare access in India, Philippines, and Sub-Saharan Africa. His recent research emphasizes equity-sensitive welfare weights and treatment gain inequality. Professional Activities: He has served as an Editor for the Journal of Health Economics since 2007 and is actively involved in peer-review and editorial work until 2026.

Brian Hieمشاهده پروفایل

استادیار

• Machine Learning
• Computational Biology
• Protein Engineering
• +۶ مورد دیگر

Brian Hie is an Assistant Professor of Chemical Engineering at Stanford University , a Dieter Schwarz Foundation Stanford Data Science Faculty Fellow , and an Innovation Investigator at Arc Institute . He leads the Laboratory of Evolutionary Design , focusing on the intersection of biology and machine learning . His prior roles include a Stanford Science Fellow in the Stanford University School of Medicine and a Visiting Researcher at Meta AI . Education: Ph.D. , Electrical Engineering and Computer Science , Massachusetts Institute of Technology (2021) Bachelor’s Degree , Stanford University Research Interests: Brian’s work bridges machine learning and computational biology , with a focus on protein engineering , single-cell RNA sequencing , and viral evolution . His Evolutionary velocity framework predicts protein evolutionary dynamics across timescales, while his Scanorama algorithm enables efficient integration of heterogeneous single-cell datasets. He also develops structure-informed language models for antibody optimization and uncertainty-aware ML for biological discovery. Publication Trends: His recent work (2023) emphasizes structure-based inverse folding for antibody evolution, evolutionary scale modeling , and unsupervised optimization . Earlier studies (2022-2021) cover evolutionary velocity , multi-modal single-cell analysis , and viral escape prediction using natural language analogies. Scientific Awards: Stanford Science Fellow (2021) National Defense Science and Engineering Graduate Fellowship (2019) Advising: He mentors doctoral students including Brandon Ameglio , Garyk Brixi , and Chang M. Yun , with a focus on biological design and computational methods . Labs & Collaborations: His lab collaborates with Bio-X and the Institute for Human-Centered Artificial Intelligence (HAI) , and he maintains affiliations with Sarafan ChEM-H and Stanford Data Science .

Outi Salo-Ahenمشاهده پروفایل

مدرس ارشد

• Pharmaceutical Chemistry
• Molecular Modeling
• Drug Design
• +۵ مورد دیگر

Senior Lecturer Outi Salo-Ahen is affiliated with Åbo Akademi University's Faculty of Natural Sciences and Engineering , Department of Pharmacy. Her research focuses on computational pharmacology, drug design, and pharmaceutical chemistry, particularly targeting chemokine receptors (CCR5/CXCR4) and transient receptor potential channels (TRPA1) for therapeutic applications. Doctor of Pharmacy (2006, University of Kuopio/UEF) MSc in Pharmaceutical Chemistry (2001, UEF) BSc in Pharmacy (1999, UEF) University Pedagogy Modules 1-5 (2012-2015) Her work contributes to UN Sustainable Development Goals through education and pharmaceutical innovation . Recent research trends include: Antimicrobial resistance solutions TRPA1 channel modulation Nanotechnology-enabled drug delivery Multi-target HIV-1 inhibitors 3D printing of biocompatible materials Computational analysis of nucleic acid frameworks She actively supervises doctoral projects, serves on assessment panels, and leads collaborations like Nordic Pharmaceutical Translation and Innovation. Her 60+ publications demonstrate expertise in molecular modeling and drug discovery.

• Immunology
• Virology
• Inflammation
• +۵ مورد دیگر

Santiago F. González is a Group Leader at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, and an extraordinary professor at the University of Italian Switzerland (USI). He earned dual PhDs in microbiology (University of Santiago de Compostela, Spain) and immunology (University of Copenhagen, Denmark), followed by postdoctoral work (2007–2011) at Harvard Medical School's Immune Disease Institute under Michael Carroll. PhD in Microbiology, University of Santiago de Compostela PhD in Immunology, University of Copenhagen His research focuses on immune system dynamics during respiratory viral infections, vaccination, and cancer metastasis. Key areas include influenza recognition , lymph node inflammation , and immune cell behavior in vivo. He pioneered studies on C-type lectin receptors (e.g., SIGN-R1) in viral immunity and epigenetic modulators for inflammation. Recent publications highlight his work in epigenetic drug development , nanovaccines , and computational tools for immune cell tracking. His group uses two-photon intravital microscopy and spatial-temporal modeling to dissect immune responses. Scientific awards include three EU Marie Curie Fellowships (2004–2013), enabling his transition to independent research. His collaborations span Harvard, USI, and European institutions, with grants from the EU and Swiss research bodies. His lab at IRB, established via the 2013 Marie Curie Career Integration Grant , develops novel imaging approaches and therapeutic strategies for infectious and immune-mediated diseases.

Paula Gonzalez-Figueroaمشاهده پروفایل

پژوهشگر ارشد

• Immunology
• Autoimmunity
• Allergy
• +۶ مورد دیگر

Dr. Paula Gonzalez-Figueroa is a Research Fellow at the Clinical Hub for Interventional Research (CHOIR) in the College of Health and Medicine at The Australian National University (ANU). She holds a PhD in Medical Sciences from ANU and completed postdoctoral research at the John Curtin School of Medical Research (ANU) and the Francis Crick Institute (UK). Her research focuses on immunology, autoimmunity, allergy, and clinical translation. Education: PhD in Medical Sciences (ANU), Biotechnology degree. Research Interests: Regulatory T cells, germinal centers, B cell biology, neuritin-based therapies, preclinical drug testing, and early-phase clinical trials. Affiliations: CHOIR (Researcher), Polizzotto Group, Genome Sciences and Cancer Division. Her work includes developing a neuritin-based biotherapeutic for allergies and autoimmune diseases, and leading preclinical/Phase I clinical programs for hematological cancers. She has contributed to studies on Tfr cell regulation, IgE responses, and germinal center dynamics. Publications span immunology, molecular biology, and translational research, with notable contributions to Nature Immunology , Cell , and Journal of Experimental Medicine .

Donald Rioمشاهده پروفایل

استاد

• Nucleic Acid Transactions
• Transposable Elements
• RNA Binding Proteins
• +۳ مورد دیگر

Donald Rio holds the Richard and Rhoda Goldman Distinguished Chair in the Biological Sciences and is a Professor of Biochemistry, Biophysics, and Structural Biology. He is affiliated with the Division of Biochemistry and Molecular Biology and the Center for Integrative Genetics. His lab focuses on nucleic acid transactions, including transposable element mobilization (P elements) and RNA binding protein mechanisms controlling alternative splicing. Research highlights include studies on THAP9 proteins in humans/zebrafish, cryo-EM structural analysis of transposase-DNA complexes, and splicing regulation in neurodegenerative diseases like ALS and Parkinson’s. His work combines biochemical, genetic, and computational approaches, including the development of the Junction Usage Model (JUM) for splicing analysis. Research interests span transposition mechanisms linked to HIV integration, immune system recombination, and evolutionary genome dynamics. His team investigates how RNA binding proteins like hnRNPA1 influence splicing in disease contexts, with projects involving CRISPR-based models and patient RNA-seq data analysis. Collaborations include studies on splicing accuracy across tissues and age, and the impact of splicing defects in neurodegenerative disorders. Key awards include the Goldman Chair. His lab’s contributions bridge fundamental molecular mechanisms with translational applications in genetic disease modeling and drug discovery. Recent work focuses on isogenic stem cell models (iSCORE-PD) for Parkinson’s research and structural biology insights into transposase function. Grants and projects involve NIH funding for ALS splicing studies and collaborations with institutions like the Buck Institute. His lab actively publishes in top journals such as Genome Research , PNAS , and Nature , with a strong emphasis on cryo-EM and bioinformatic methods.

Wei-Jen Tangمشاهده پروفایل

استاد

• Structural Biology
• Biochemistry
• Molecular Biology
• +۴ مورد دیگر

Wei-Jen Tang is a Professor at the University of Chicago, affiliated with the Ben May Department of Cancer Research. His work integrates structural biology and biochemistry to study protein interactions critical to human health, particularly in Alzheimer's disease, diabetes, and bacterial pathogenesis. Education: B.S. in Zoology, National Taiwan University; Ph.D. in Biological Sciences, University of Texas, Austin; Postdoctoral training in Virology and Pharmacology at University of Texas Southwestern. His research focuses on: Amyloid Peptide-Degrading Proteases: IDE and PreP for Alzheimer's and diabetes. Chemokines: CCL5 and CCL3 in inflammation and HIV. Bacterial Toxins: Edema factor in anthrax and bio-defense. Recent publications highlight structural insights into IDE, PreP, and anthrax toxins, with keywords spanning Structural Biology , Biochemistry , and Therapeutics . Funding includes NIH and American Heart Association grants. Awards include AHA Established Investigator and Cancer Research Foundation Young Investigator. Lab updates note new members and a 2025 publication on PreP.